

Keith A Rodvold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5841672/publications.pdf>

Version: 2024-02-01

93
papers

5,770
citations

126907

33
h-index

76900

74
g-index

94
all docs

94
docs citations

94
times ranked

5935
citing authors

#	ARTICLE	IF	CITATIONS
1	Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update. <i>Clinical Pharmacokinetics</i> , 2022, 61, 17-46.	3.5	26
2	Authors' Reply to De Sutter, De Waele, and Vermeulen: Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update. <i>Clinical Pharmacokinetics</i> , 2022, 61, 337-338.	3.5	0
3	Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	3
4	Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2902-2905.	3.0	30
5	60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin. <i>Clinical Infectious Diseases</i> , 2020, 70, 1546-1549.	5.8	11
6	Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 2020, 59, 409-425.	3.5	22
7	Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	32
8	1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia. <i>Open Forum Infectious Diseases</i> , 2020, 7, S668-S668.	0.9	4
9	Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. <i>Clinical Infectious Diseases</i> , 2019, 69, S16-S22.	5.8	34
10	Omadacycline: a novel aminomethylcycline. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1895-1915.	2.7	21
11	The Infectious Diseases Society of America's 10-20 Initiative (10 New Systemic Antibacterial Agents US). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 69, 1-11.	5.8	120
12	ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections. <i>Future Microbiology</i> , 2019, 14, 461-475.	2.0	6
13	Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iii2-iii4.	3.0	14
14	Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 710-715.	2.0	9
15	Renal Dosing of Antibiotics: Are We Jumping the Gun?. <i>Clinical Infectious Diseases</i> , 2019, 68, 1596-1602.	5.8	85
16	Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	23
17	Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	8
18	Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	29

#	ARTICLE	IF	CITATIONS
19	Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	24
20	Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	35
21	Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1007-1021.	3.3	18
22	Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 463-472.	3.3	5
23	Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	32
24	Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. <i>Current Opinion in Pharmacology</i> , 2017, 36, 114-123.	3.5	59
25	Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	86
26	Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	15
27	A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration. <i>Open Forum Infectious Diseases</i> , 2017, 4, S529-S530.	0.9	4
28	Clearance of ceftazidime-avibactam in an in vitro continuous venovenous hemodialysis model. <i>Open Forum Infectious Diseases</i> , 2017, 4, S294-S295.	0.9	2
29	Pharmacokinetics, pharmacodynamics, and safety of <sc>USL</sc>261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. <i>Epilepsia</i> , 2015, 56, 1723-1731.	5.1	25
30	Editorial Commentary: Improving Prescribers to Advance Antimicrobial Stewardship. <i>Clinical Infectious Diseases</i> , 2015, 60, 1259-1261.	5.8	3
31	Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3956-3965.	3.2	27
32	Telavancin for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. <i>Clinical Infectious Diseases</i> , 2015, 61, S35-S37.	5.8	1
33	Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions. <i>Clinical Infectious Diseases</i> , 2015, 61, S38-S47.	5.8	25
34	Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7232-7239.	3.2	88
35	Penetration of GSK1322322 into Epithelial Lining Fluid and Alveolar Macrophages as Determined by Bronchoalveolar Lavage. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 419-423.	3.2	9
36	Methicillin-Resistant <i>Staphylococcus aureus</i> Therapy: Past, Present, and Future. <i>Clinical Infectious Diseases</i> , 2014, 58, S20-S27.	5.8	279

#	ARTICLE	IF	CITATIONS
37	Variability in Telavancin Cross-Reactivity among Vancomycin Immunoassays. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7093-7097.	3.2	12
38	Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1741-1750.	3.3	11
39	Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 178-187.	1.8	25
40	Innovative approaches to optimizing the delivery of vancomycin in individual patients. <i>Advanced Drug Delivery Reviews</i> , 2014, 77, 50-57.	13.7	215
41	Intrapulmonary Pharmacokinetics of GSK2251052 in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3334-3339.	3.2	16
42	National survey on continuous and extended infusions of antibiotics. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1895-1904.	1.0	9
43	Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2463-2469.	3.0	108
44	Comparison of Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Solithromycin (CEM-101) in Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5076-5081.	3.2	49
45	Penetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5507-5511.	3.2	51
46	Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid. <i>Clinical Pharmacokinetics</i> , 2011, 50, 689-704.	3.5	68
47	Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid. <i>Clinical Pharmacokinetics</i> , 2011, 50, 637-664.	3.5	190
48	Zanamivir Pharmacokinetics and Pulmonary Penetration into Epithelial Lining Fluid following Intravenous or Oral Inhaled Administration to Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5178-5184.	3.2	28
49	Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2010, 50, 133-164.	5.8	1,260
50	Drug interactions involving anti-infective agents. , 2010, , 68-103.		2
51	Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Surgical Infections</i> , 2010, 11, 79-109.	1.4	401
52	Collaborative Strategies for Improving Clinical Resource Utilization: How Pharmacists Can Make a Difference. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 10-14.	2.2	1
53	Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3294-3301.	3.2	64
54	START Learning by Sharing: FAQs. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 24-26.	2.2	1

#	ARTICLE	IF	CITATIONS
55	Journal of Managed Care Pharmacy. START (Stewardship Tactics for Antimicrobial Resistance Trends). Introduction. Journal of Managed Care Pharmacy, 2009, 15, S3-4.	2.2	0
56	The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opinion on Pharmacotherapy, 2008, 9, 561-575.	1.8	46
57	Tigecycline: A Novel Broad-Spectrum Antimicrobial. Annals of Pharmacotherapy, 2007, 41, 965-972.	1.9	60
58	Antibiotic Drug Interactions. Medical Clinics of North America, 2006, 90, 1223-1255.	2.5	58
59	Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagnostic Microbiology and Infectious Disease, 2006, 55, 303-309.	1.8	44
60	Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. Journal of Antimicrobial Chemotherapy, 2006, 58, 1221-1229.	3.0	272
61	Daptomycin: A novel cyclic lipopeptide antimicrobial. American Journal of Health-System Pharmacy, 2005, 62, 1145-1158.	1.0	72
62	Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration. American Journal of Health-System Pharmacy, 2005, 62, 88-92.	1.0	2
63	Antibiotic Optimization: Concepts and Strategies in Clinical Practice Edited by Robert C. Owens, Jr., Paul G. Ambrose, and Charles H. Nightingale New York: Marcel Dekker, 2005. 663 pp., illustrated. \$179.95 (cloth). Clinical Infectious Diseases, 2005, 41, 1828-1828.	5.8	0
64	Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2004, 48, 4597-4605.	3.2	25
65	Sex-Related Differences in the Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsules Boosted with Low-Dose Ritonavir in Patients Infected with Human Immunodeficiency Virus Type 1. Pharmacotherapy, 2004, 24, 592-599.	2.6	32
66	Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study. Current Therapeutic Research, 2004, 65, 1-12.	1.2	18
67	Safety and tolerability of fluoroquinolones. Clinical Cornerstone, 2003, 5, S29-S36.	0.7	44
68	Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2003, 47, 2450-2457.	3.2	102
69	Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. Journal of Antimicrobial Chemotherapy, 2003, 52, 450-456.	3.0	23
70	Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. Pharmacotherapy, 2001, 21, 233S-252S.	2.6	85
71	Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside. Pharmacotherapy, 2001, 21, 319S-330S.	2.6	36
72	Steady-State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects. Chest, 2001, 119, 1114-1122.	0.8	156

#	ARTICLE	IF	CITATIONS
73	National Survey of Extended-Interval Aminoglycoside Dosing. <i>Clinical Infectious Diseases</i> , 2000, 30, 433-439.	5.8	105
74	Dosage Adjustments for Antibacterials in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2000, 38, 415-426.	3.5	101
75	Clinical Pharmacokinetics of Clarithromycin. <i>Clinical Pharmacokinetics</i> , 1999, 37, 385-398.	3.5	187
76	Therapeutic Drug Monitoring of Vancomycin in a Morbidly Obese Patient. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 261-265.	2.0	32
77	Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children. <i>Clinical Pharmacokinetics</i> , 1997, 33, 32-51.	3.5	84
78	IV Cefuroxime Plus Oral Clarithromycin or IV Erythromycin for the Treatment of Community-Acquired Pneumonia in Hospitalised Patients. <i>Clinical Drug Investigation</i> , 1997, 14, 23-34.	2.2	2
79	Antimicrobial Dosing in Obese Patients. <i>Clinical Infectious Diseases</i> , 1997, 25, 112-118.	5.8	151
80	Single daily doses of aminoglycosides. <i>Lancet, The</i> , 1997, 350, 1412.	13.7	15
81	Bayesian Forecasting of Serum Vancomycin Concentrations in Neonates and Infants. <i>Therapeutic Drug Monitoring</i> , 1995, 17, 239-246.	2.0	33
82	How Important Is Therapeutic Drug Monitoring in the Prediction and Avoidance of Adverse Reactions?. <i>Drug Safety</i> , 1995, 12, 359-363.	3.2	8
83	Prediction of Acetaminophen Concentrations in Overdose Patients Using a Bayesian Pharmacokinetic Model. <i>Journal of Toxicology: Clinical Toxicology</i> , 1994, 32, 17-30.	1.5	2
84	Cost Considerations in Therapeutic Drug Monitoring of Aminoglycosides. <i>Clinical Pharmacokinetics</i> , 1994, 26, 71-81.	3.5	29
85	New Oral Macrolide and Fluoroquinolone Antibiotics: An Overview of Pharmacokinetics, Interactions, and Safety. <i>Clinical Infectious Diseases</i> , 1993, 17, S192-S199.	5.8	61
86	Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery. <i>Pediatric Infectious Disease Journal</i> , 1993, 12, 300-303.	2.0	22
87	Methods of Minimising the Cost of Aminoglycoside Therapy to Hospitals. <i>Pharmacoeconomics</i> , 1993, 3, 228-243.	3.3	9
88	Phenobarbital Pharmacokinetics in Obesity. <i>Clinical Pharmacokinetics</i> , 1992, 22, 481-484.	3.5	12
89	An Updated Comparison of Drug Dosing Methods. <i>Clinical Pharmacokinetics</i> , 1991, 20, 209-217.	3.5	13
90	An Updated Comparison of Drug Dosing Methods. <i>Clinical Pharmacokinetics</i> , 1991, 20, 280-292.	3.5	12

#	ARTICLE	IF	CITATIONS
91	An Updated Comparison of Drug Dosing Methods. <i>Clinical Pharmacokinetics</i> , 1991, 20, 374-388.	3.5	32
92	An Updated Comparison of Drug Dosing Methods. <i>Clinical Pharmacokinetics</i> , 1991, 20, 463-476.	3.5	41
93	Bayesian Forecasting of Serum Gentamicin Concentrations in Intensive Care Patients. <i>Clinical Pharmacokinetics</i> , 1990, 18, 409-418.	3.5	18